title: Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
abstract: Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency virus type 1 (HIV) DNA level. However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activation after antiretroviral therapy remain unknown. Our study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the IFN group (n = 10). No changes were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA, or 2-long-terminal repeat circles, although APOBEC3G, TRIM5α, BST2, and TRIM22 were upregulated in the IFN group. These data suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part through inhibition of HIV transcription by TRIM22 and decrease in T-cell activation.
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Sara
authors.initials: S
authors.lastname: Morón-López
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Gómez-Mora
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Maria
authors.initials: M
authors.lastname: Salgado
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Dan
authors.initials: D
authors.lastname: Ouchi
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Puertas
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona.
authors.forename: Víctor
authors.initials: V
authors.lastname: Urrea
authors.affiliation: Infectious Diseases Department, Hospital Universitari Vall d'Hebron.
authors.forename: Jordi
authors.initials: J
authors.lastname: Navarro
authors.affiliation: Fundació Lluita Contra la SIDA, Badalona.
authors.forename: Antoni
authors.initials: A
authors.lastname: Jou
authors.affiliation: Infectious Diseases Department, Hospital Universitari Vall d'Hebron.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Pérez
authors.affiliation: Fundació Lluita Contra la SIDA, Badalona.
authors.forename: Cristina
authors.initials: C
authors.lastname: Tural
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona Fundació Lluita Contra la SIDA, Badalona Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.affiliation: The Wistar Institute, Philadelphia, Pennsylvania.
authors.forename: Luis J
authors.initials: LJ
authors.lastname: Montaner
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
authors.forename: Julià
authors.initials: J
authors.lastname: Blanco
authors.affiliation: Infectious Diseases Department, Hospital Universitari Vall d'Hebron.
authors.forename: Manuel
authors.initials: M
authors.lastname: Crespo
authors.affiliation: AIDS Research Institute IrsiCaixa, Institut d'Investigació en Cièncias de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona Institució Catalana de Recerca i Estudis Avançats, Barcelona Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Martinez-Picado
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers; D015496:CD4-Positive T-Lymphocytes / Q000145:classification / Q000187:drug effects* / Q000502:physiology; D060085:Coinfection; D005260:Female; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology*; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D015415:Biomarkers; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: CD4+ T-cell subpopulations; HIV RNA expression; HIV persistence; HIV/HCV coinfection; IFN alfa; Siglec-1; TRIM22; immune activation